Caxton Associates LLP Xeris Biopharma Holdings, Inc. Transaction History
Caxton Associates LLP
- $2.87 Trillion
- Q1 2025
A detailed history of Caxton Associates LLP transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Caxton Associates LLP holds 30,938 shares of XERS stock, worth $150,977. This represents 0.01% of its overall portfolio holdings.
Number of Shares
30,938Holding current value
$150,977% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding XERS
# of Institutions
203Shares Held
84.7MCall Options Held
132KPut Options Held
69.4K-
Black Rock Inc. New York, NY10.3MShares$50.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.11MShares$39.6 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.29MShares$20.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.41MShares$16.6 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$16.2 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $663M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...